Supress Dm

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary control of cough due to minor throat and bronchial irritation, which may occur with a cold. It also aids in loosening phlegm (mucus) and thinning bronchial secretions, facilitating the clearance of bothersome mucus from the bronchial passageways. By promoting drainage of the bronchial tubes, this medication enhances the productivity of coughs.

Dosage and Administration

For children aged 6 to under 12 years, the recommended dosage is 1 mL administered every 4 hours as needed. It is important not to exceed 6 doses within a 24-hour period unless otherwise directed by a healthcare professional.

For children under 6 years of age, it is advised to consult a doctor prior to administration to determine the appropriate dosage and ensure safety.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

The use of this product is contraindicated in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or have taken one within the past two weeks. MAOIs are commonly prescribed for depression, psychiatric or emotional conditions, and Parkinson's disease. Healthcare professionals should advise caregivers to consult a doctor or pharmacist if there is uncertainty regarding the presence of an MAOI in the child's prescription medication.

Prior to administration, it is essential to consult a healthcare provider if the child presents with a cough that is productive of excessive phlegm or if the cough is chronic, as seen in conditions such as asthma. Caregivers should be instructed to adhere strictly to the recommended dosage and to avoid exceeding it during treatment.

Patients should be advised to discontinue use and seek medical attention if new symptoms arise, if the cough persists for more than one week, or if it recurs and is accompanied by fever, rash, or a persistent headache. These symptoms may indicate a serious underlying condition that requires further evaluation.

In the event of an accidental overdose, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious warnings include the contraindication of use in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within two weeks of discontinuing such medication. MAOIs are typically prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease.

Before administering this medication to a child, it is advisable to consult a healthcare professional if the child has a cough that is productive with excessive phlegm or if the cough is chronic, as may occur in conditions such as asthma.

Patients are also advised to discontinue use and seek medical advice if new symptoms arise, if coughs persist for more than one week, or if the cough tends to recur and is accompanied by fever, rash, or a persistent headache. These symptoms may indicate a serious underlying condition.

In the event of an accidental overdose, it is crucial to obtain medical assistance immediately or contact a Poison Control Center for guidance.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Supress Dm (dextromethorphan hydrobromide, guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should not use this medication if they are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of discontinuing an MAOI. Prior to administration, it is advisable to consult a healthcare professional if the child has a cough associated with excessive phlegm (mucus) or a chronic cough, such as that which occurs with asthma.

For children aged 6 to under 12 years, the recommended dosage is 1 mL every 4 hours as needed, with a maximum of 6 doses in a 24-hour period, unless otherwise directed by a physician. For children under 6 years of age, consultation with a healthcare provider is required before use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to discuss their individual circumstances with a healthcare provider to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an accidental overdose, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt action is crucial to mitigate potential adverse effects associated with overdosage.

Healthcare professionals should be aware that symptoms of overdose may vary depending on the specific substance involved. Therefore, a thorough assessment of the patient's condition is essential to determine the appropriate course of action.

Management of an overdose typically involves supportive care and symptomatic treatment. Continuous monitoring of the patient's vital signs and clinical status is recommended. In cases where specific antidotes are available, their administration should be considered based on the clinical scenario.

It is vital for healthcare providers to remain vigilant and prepared to implement emergency protocols in the event of an overdose, ensuring the best possible outcomes for affected individuals.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified in the available data. Additionally, there are no detailed findings regarding nonclinical toxicology or animal pharmacology and toxicology provided in the current information.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions reported voluntarily or through surveillance programs. These include allergic reactions such as rash, pruritus, and urticaria. Neurological effects such as dizziness and drowsiness have also been noted, along with gastrointestinal disturbances including nausea and vomiting.

Additionally, cases of confusion and hallucinations have been reported. Cardiovascular effects, specifically increased heart rate (tachycardia), have been observed. Respiratory depression has been documented, as well as instances of serotonin syndrome, particularly when the product is used in conjunction with other serotonergic agents.

Concerns regarding abuse potential and dependence have been raised, alongside reports of misuse and overdose. Furthermore, withdrawal symptoms have been noted upon discontinuation after prolonged use.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. It is important to emphasize the potential risks associated with overdose. In the event of an accidental overdose, patients should be instructed to seek medical help immediately or contact a Poison Control Center for assistance. This information is crucial for ensuring patient safety and promoting responsible use of the medication.

Storage and Handling

The product is supplied in configurations that include specific NDC numbers. It should be stored at a controlled room temperature ranging from 15° to 30°C (59° to 86°F). Care should be taken to avoid exposure to excessive heat and humidity, as these conditions may compromise the integrity of the product. Additionally, the product must not be used if the cap seal is torn, broken, or missing, as this indicates potential contamination or degradation.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Supress Dm, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)